Alina M Mateo1, Todd A Pezzi2, Mark Sundermeyer3, Cynthia A Kelley4, Vicki S Klimberg5, Christopher M Pezzi6. 1. Department of Surgery, Abington Hospital-Jefferson Health, Abington, Pennsylvania. mateo.alina@gmail.com. 2. Baylor College of Medicine, Houston, Texas. 3. Department of Medicine, Abington Hospital-Jefferson Health, Abington, Pennsylvania. 4. Department of Pathology, Abington Hospital-Jefferson Health, Abington, Pennsylvania. 5. Department of Surgery, University of Arkansas for Medical Sciences, Little Rock, Arkansas. 6. Department of Surgery, Abington Hospital-Jefferson Health, Abington, Pennsylvania.
Abstract
BACKGROUNDS AND OBJECTIVES: Medullary breast carcinoma (MBC) is a subtype with a more favorable prognosis. Tumors with some, but not all, characteristics of MBC are classified as atypical medullary carcinoma of the breast (AMCB). METHODS: Patients with invasive MBC and AMCB reported to the National Cancer Data Base (NCDB) from 2004 to 2013 were compared for tumor characteristics and overall survival, using infiltrating ductal carcinoma (IDC) as a reference. RESULTS: Patients with MBC (n = 3,688), AMCB (n = 288), and IDC (n = 918,870) met inclusion criteria. Comparing MBC with AMCB, the mean age at diagnosis (52.9 vs. 53.9 years), mean tumor size (2.4 vs. 2.5 cm), lymph node positivity (22.8% vs. 22.4%), estrogen receptor (ER) positivity (22% vs. 25%), progesterone receptor (PR) positivity (14% vs. 15%), HER2 positivity (11% vs. 14%), rate of breast conserving surgery (67% vs. 68%), use of chemotherapy (76% vs. 75%), and use of hormonal therapy (19% vs. 18%), respectively, were not clinically or statistically different. Five-year (92% vs. 89%) and 10-year survival rates (85% vs. 87%) were not significantly different (P = 0.46). CONCLUSIONS: There does not appear to be any reason to differentiate between AMCB and MBC given the similarities in presentation, treatment and prognosis. J. Surg. Oncol. 2016;114:533-536.
BACKGROUNDS AND OBJECTIVES: Medullary breast carcinoma (MBC) is a subtype with a more favorable prognosis. Tumors with some, but not all, characteristics of MBC are classified as atypical medullary carcinoma of the breast (AMCB). METHODS:Patients with invasive MBC and AMCB reported to the National Cancer Data Base (NCDB) from 2004 to 2013 were compared for tumor characteristics and overall survival, using infiltrating ductal carcinoma (IDC) as a reference. RESULTS:Patients with MBC (n = 3,688), AMCB (n = 288), and IDC (n = 918,870) met inclusion criteria. Comparing MBC with AMCB, the mean age at diagnosis (52.9 vs. 53.9 years), mean tumor size (2.4 vs. 2.5 cm), lymph node positivity (22.8% vs. 22.4%), estrogen receptor (ER) positivity (22% vs. 25%), progesterone receptor (PR) positivity (14% vs. 15%), HER2 positivity (11% vs. 14%), rate of breast conserving surgery (67% vs. 68%), use of chemotherapy (76% vs. 75%), and use of hormonal therapy (19% vs. 18%), respectively, were not clinically or statistically different. Five-year (92% vs. 89%) and 10-year survival rates (85% vs. 87%) were not significantly different (P = 0.46). CONCLUSIONS: There does not appear to be any reason to differentiate between AMCB and MBC given the similarities in presentation, treatment and prognosis. J. Surg. Oncol. 2016;114:533-536.
Authors: Felipe C Geyer; Fresia Pareja; Britta Weigelt; Emad Rakha; Ian O Ellis; Stuart J Schnitt; Jorge S Reis-Filho Journal: Am J Pathol Date: 2017-07-20 Impact factor: 4.307
Authors: Michał P Budzik; Maciej T Sobieraj; Maria Sobol; Janusz Patera; Aleksandra Czerw; Andrzej Deptała; Anna M Badowska-Kozakiewicz Journal: Arch Med Sci Date: 2019-07-17 Impact factor: 3.318
Authors: Markus Rechsteiner; Konstantin Dedes; Daniel Fink; Bernhard Pestalozzi; Bettina Sobottka; Holger Moch; Peter Wild; Zsuzsanna Varga Journal: J Cancer Res Clin Oncol Date: 2018-02-17 Impact factor: 4.553